Drug intelligence / Profile preview

SYGN313

Development stage: Preclinical
Lead developer: Synedgen
Modality: Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral, Intravenous, Subcutaneous, Intramuscular, Topical

Overview

SYGN313 is a proprietary glycopolymer pharmaceutical developed by Synedgen. It is currently undergoing preclinical efficacy studies with the goal of advancing treatments for inflammatory bowel disease (IBD), specifically ulcerative colitis (UC). The development focuses on optimizing the drug's structure and dosing in animal models prior to clinical development.

Beyond the preview

Go deeper on SYGN313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYGN313.

Explore the full profile